MetaCap

InMode Financial Ratios

NASDAQ: INMDHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

14.21+0.13 (+0.92%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

InMode ratio analysis

InMode earned a net margin of 25.3% in FY 2025, down from 45.9% a year earlier. Gross margin was 78.5% compared with a median of 84.4% over the prior 8 years. Return on equity reached 13.7%, meaning InMode generated 0.14 dollars of profit for every dollar of shareholders' equity.

At the end of FY 2025, INMD traded at 10.3 times earnings; across the 7 fiscal years shown, its year-end P/E ranged from 7.6 to 36.8, with a median of 18.9. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

InMode financial ratios (annual)

InMode annual financial ratios
RatioFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
P/E ratio (at fiscal year end)10.357.569.6718.8936.7626.6723.03——
Price / sales2.583.423.786.4816.088.316.89——
Price / book1.401.922.365.3113.826.746.12——
Gross margin78.5%80.3%83.6%83.8%85.0%85.0%87.1%85.0%83.1%
Operating margin23.0%28.5%39.8%43.6%46.8%35.3%38.1%23.5%16.7%
Net margin25.3%45.9%40.2%35.6%46.1%36.4%39.1%22.3%16.5%
Free cash flow margin22.7%33.4%35.8%39.6%48.6%38.2%39.3%36.4%27.0%
Return on equity (ROE)13.7%25.8%25.1%29.1%39.7%29.5%34.7%51.7%45.3%
Return on assets (ROA)12.2%23.1%22.9%25.1%34.5%25.4%28.0%27.6%—
Current ratio9.8810.2313.187.679.078.276.562.64—
Revenue growth-6.2%-19.8%8.3%27.0%73.5%31.8%56.1%87.4%—
EPS growth-36.4%-2.2%21.7%-1.6%115.7%11.2%29.0%138.5%—

Related